MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/hem3.70388

Медицинская библиотека · HemaSphere · 2026

Varnimcabtagene autoleucel (ARI-0001) in relapsed or refractory mantle cell lymphoma.

Albiol Nil, Martínez-Cibrián Nuria, Pérez Amanda Isabel, Navarro-Velázquez Sergio, Muzzi Guilherme, Oliver-Caldes Aina, Español-Rego Marta, Alserawan Leticia, Montoro-Lorite Mercedes, Ramos Carla, Ayora Pilar, Martin-López Ana África, Cabero Almudena, Pérez-López Estefanía, García-Sancho Alejandro Martín, Baumann Tycho, Sánchez-Pina José María, Chinea Anabelle, Fernández-Caldas Paula, Bastos-Oreiro Mariana, Kwon Mi, Rodríguez-Lobato Luis Gerardo, Magnano Laura, Rivero Andrea, Correa Juan G, Mozas Pablo, Sánchez-Castañón María, Mata-Molanes Juan J, Charry Paola, Álamo Jose R, Setoaín Xavier, Rodríguez Sonia, Olesti Eulalia, Sáez-Peñataro Joaquín, Fernández de Larrea Carlos, Urbano-Ispizua Álvaro, López-Guillermo Armando, Delgado Julio, González-Navarro E Azucena, Juan Manel, Giné Eva, Ortiz-Maldonado Valentín

СтатьяПеревод в очереди

Аннотация

Varnimcabtagene autoleucel (var-cel) is an autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy administered using an adaptive, fractionated dosing strategy. We conducted a multicenter retrospective study to evaluate the safety and efficacy of var-cel in patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL) treated at four Spanish centers, including patients enrolled in the CART19-BE-01 trial and a subsequent compassionate use program. Thirty patients underwent leukapheresis; 27 received var-cel following lymphodepletion and fractionated infusion in three escalating doses (0.1 to 5 × 106 CAR T cells/kg). Any-grade cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) occurred in 93% and 4%, respectively, with Grade ≥3 CRS and/or ICANS observed in a single patient (4%). The overall response rate among infused patients was 89% (95% CI, 71-98), including 78% complete responses (95% CI, 58-91). Median duration of response and progression-free survival were 17.1 and 15.4 months, respectively. With a median follow-up of 21.7 months, median overall survival was 35.2 months. In this multicenter academic experience, var-cel demonstrated high antitumor activity with low rates of severe CRS and ICANS, supporting its use within a coordinated national network.

Для цитирования: Albiol Nil, Martínez-Cibrián Nuria, Pérez Amanda Isabel, Navarro-Velázquez Sergio, Muzzi Guilherme, Oliver-Caldes Aina, Español-Rego Marta, Alserawan Leticia, Montoro-Lorite Mercedes, Ramos Carla, Ayora Pilar, Martin-López Ana África, Cabero Almudena, Pérez-López Estefanía, García-Sancho Alejandro Martín, Baumann Tycho, Sánchez-Pina José María, Chinea Anabelle, Fernández-Caldas Paula, Bastos-Oreiro Mariana, Kwon Mi, Rodríguez-Lobato Luis Gerardo, Magnano Laura, Rivero Andrea, Correa Juan G, Mozas Pablo, Sánchez-Castañón María, Mata-Molanes Juan J, Charry Paola, Álamo Jose R, Setoaín Xavier, Rodríguez Sonia, Olesti Eulalia, Sáez-Peñataro Joaquín, Fernández de Larrea Carlos, Urbano-Ispizua Álvaro, López-Guillermo Armando, Delgado Julio, González-Navarro E Azucena, Juan Manel, Giné Eva, Ortiz-Maldonado Valentín. Varnimcabtagene autoleucel (ARI-0001) in relapsed or refractory mantle cell lymphoma.. HemaSphere. 2026. DOI: 10.1002/hem3.70388.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.